drugset / Trial / NCT02167711

Treatment for Bile Duct Cancer in the Liver

NCT02167711

Phase 2 Completed 24 enrolled Chinese University of Hong Kong
NaSingle-groupOpen-labelTreatment

Summary

The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy. The use of selective internal radiotherapy treatment (SIRT-Y90) is proven efficacious in patients with intra-heptic tumor. Previous experience with SIRT is safe in patients with intrahepatic cholangiocarcinoma. This study aims to study the benefits of sequential administration of SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma.

Timeline

Start
2014-09-17
Primary completion
2023-01-31
Completion
2023-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Gemcitabine Small molecule
Subject Yttrium-90 Other / unclassified